Utility of DAT in Low-Risk Neonates with ABO or RhD Incompatibility

BACKGROUND: Routine direct antiglobulin test (DAT) screening in newborns at risk of isoimmune hemolytic disease is a long-standing practice. Advancements in prophylactic care and noninvasive hyperbilirubinemia monitoring warrant reevaluating the value of DAT. We investigated the clinical utility of routine DAT screening for mature newborns with ABO incompatibility and ABO-compatible newborns with RhD incompatibility born to mothers without active alloimmunization. METHODS: We conducted a retrospective cohort study of infants born after 35 weeks or more of gestation undergoing DAT screening. Infants were stratified into ABO-incompatible and ABO-compatible/RhD-incompatible cohorts. Bivariable correlations, logistic regression, and area under the receiver operating characteristic curve (AUC) were used to assess predictors for phototherapy requirements. RESULTS: Among 618 infants included in the analysis, within the ABO-incompatible cohort (N = 310), DAT positivity was associated with higher transcutaneous bilirubin (TcB) and increased phototherapy requirement. However, TcB alone robustly predicted the phototherapy requirement (AUC = 0.887). Incorporating DAT minimally enhanced the predictive capacity (AUC = 0.896). In the ABO-compatible/RhD-incompatible cohort (N = 308), 14.0% of infants had a positive DAT attributed to passive maternal anti-D, showing no correlation with TcB. Only 1.0% of these infants required phototherapy. CONCLUSIONS: Our data showed routine DAT screening provides minimal predictive value beyond TcB monitoring for ABO-incompatible infants and offers no clinical utility for RhD-incompatible infants exposed solely to passive anti-D. These findings validate the 2022 American Academy of Pediatrics guidelines, suggesting that discontinuing routine DAT in these low-risk populations safely optimizes laboratory resources. Importantly, maternal antibody screening remains essential, and DAT must be performed if maternal screening is incomplete or unavailable.

Authors

Institutions

Publication Details

Journal
PEDIATRICS
Published
2026-08-26
DOI
https://doi.org/10.1542/peds.2026-076989
Primary Topic
Neonatal Health and Biochemistry
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Utility of DAT in Low-Risk Neonates with ABO or RhD Incompatibility

Ting‐Lan Ma, Theresa Nester, Tsung‐Lin Tsai
PEDIATRICS
Neonatal Health and Biochemistry
article

Utility of DAT in Low-Risk Neonates with ABO or RhD Incompatibility

Ting‐Lan Ma, Theresa Nester, Tsung‐Lin Tsai
article en

Abstract

BACKGROUND: Routine direct antiglobulin test (DAT) screening in newborns at risk of isoimmune hemolytic disease is a long-standing practice. Advancements in prophylactic care and noninvasive hyperbilirubinemia monitoring warrant reevaluating the value of DAT. We investigated the clinical utility of routine DAT screening for mature newborns with ABO incompatibility and ABO-compatible newborns with RhD incompatibility born to mothers without active alloimmunization. METHODS: We conducted a retrospective cohort study of infants born after 35 weeks or more of gestation undergoing DAT screening. Infants were stratified into ABO-incompatible and ABO-compatible/RhD-incompatible cohorts. Bivariable correlations, logistic regression, and area under the receiver operating characteristic curve (AUC) were used to assess predictors for phototherapy requirements. RESULTS: Among 618 infants included in the analysis, within the ABO-incompatible cohort (N = 310), DAT positivity was associated with higher transcutaneous bilirubin (TcB) and increased phototherapy requirement. However, TcB alone robustly predicted the phototherapy requirement (AUC = 0.887). Incorporating DAT minimally enhanced the predictive capacity (AUC = 0.896). In the ABO-compatible/RhD-incompatible cohort (N = 308), 14.0% of infants had a positive DAT attributed to passive maternal anti-D, showing no correlation with TcB. Only 1.0% of these infants required phototherapy. CONCLUSIONS: Our data showed routine DAT screening provides minimal predictive value beyond TcB monitoring for ABO-incompatible infants and offers no clinical utility for RhD-incompatible infants exposed solely to passive anti-D. These findings validate the 2022 American Academy of Pediatrics guidelines, suggesting that discontinuing routine DAT in these low-risk populations safely optimizes laboratory resources. Importantly, maternal antibody screening remains essential, and DAT must be performed if maternal screening is incomplete or unavailable.

PEDIATRICS
Uniformed Services University of the Health Sciences (US), University of Washington (US), Bloodworks Northwest (US), LifeWorks Northwest (US), University of Washington Applied Physics Laboratory (US)
Good health and well-being
Openalex Percentile: Top 7%
Neonatal Health and Biochemistry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.